Victory Capital Management Inc. Buys Shares of 543,525 Kala Pharmaceuticals, Inc. (KALA)
Victory Capital Management Inc. bought a new stake in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 543,525 shares of the company’s stock, valued at approximately $12,414,000. Victory Capital Management Inc. owned 2.24% of Kala Pharmaceuticals as of its most recent SEC filing.
Shares of Kala Pharmaceuticals, Inc. (KALA) opened at $19.94 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00. Kala Pharmaceuticals, Inc. has a one year low of $13.51 and a one year high of $26.75.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.14). sell-side analysts anticipate that Kala Pharmaceuticals, Inc. will post -2.08 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Victory Capital Management Inc. Buys Shares of 543,525 Kala Pharmaceuticals, Inc. (KALA)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/14/victory-capital-management-inc-buys-shares-of-543525-kala-pharmaceuticals-inc-kala.html.
A number of brokerages recently issued reports on KALA. Oppenheimer Holdings, Inc. began coverage on Kala Pharmaceuticals in a research report on Tuesday, August 15th. They issued an “outperform” rating and a $46.00 target price for the company. Zacks Investment Research cut Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Bank of America Corporation began coverage on Kala Pharmaceuticals in a research report on Monday, August 14th. They issued a “buy” rating and a $33.00 target price for the company. Wedbush initiated coverage on Kala Pharmaceuticals in a research report on Monday, August 14th. They issued an “outperform” rating and a $46.00 target price for the company. Finally, J P Morgan Chase & Co initiated coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They set an “overweight” rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Kala Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $36.80.
Kala Pharmaceuticals Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Want to see what other hedge funds are holding KALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kala Pharmaceuticals, Inc. (NASDAQ:KALA).
Receive News & Stock Ratings for Kala Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.